SNA 125

Drug Profile

SNA 125

Alternative Names: CT 340; SNA 125

Latest Information Update: 21 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Creabilis SA
  • Developer Creabilis SA; Sienna Biopharmaceuticals
  • Class
  • Mechanism of Action Janus kinase 3 inhibitors; MAP2K3 protein inhibitors; TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atopic dermatitis; Pruritus; Psoriasis
  • Discontinued Arthritis; Neuropathic pain; Pain; Scars

Most Recent Events

  • 07 Sep 2017 Sienna Biopharmaceuticals plans a clinical trial for Atopic dermatitis and Psoriasis in the first half of 2018
  • 21 Mar 2017 Discontinued - Preclinical for Neuropathic pain in Luxembourg (Topical) (Sienna pipeline, March 2017)
  • 21 Mar 2017 Discontinued for Scars, Pain and Arthritis in Luxembourg (Topical) (Sienna pipeline, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top